{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:34Z","timestamp":1740148234172,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"science and technology planning project of Wenzhou city","award":["2021Y0946"],"award-info":[{"award-number":["2021Y0946"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03581-7","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T10:01:48Z","timestamp":1720864908000},"page":"785-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low dose of dexamethasone combined with netupitant and palonosetron in preventing nausea and vomiting in breast cancer patients induced by anthracycline drugs"],"prefix":"10.1007","volume":"27","author":[{"given":"Yehuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9592-8123","authenticated-orcid":false,"given":"Suxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"7","key":"3581_CR1","first-page":"517","volume":"34","author":"WQ Chen","year":"2012","unstructured":"Chen WQ, Zheng RS. Trend analysis and projection of cancer incidence in China between 1989 and 2008. Chin J Oncol. 2012;34(7):517\u201324.","journal-title":"Chin J Oncol"},{"key":"3581_CR2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2016.17.4.1661","author":"DM Yuan","year":"2016","unstructured":"Yuan DM, Li Q, Zhang Q, et al. Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev. 2016. https:\/\/doi.org\/10.7314\/APJCP.2016.17.4.1661.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"3581_CR3","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41564-022-01257-y","volume":"7","author":"D Megrian","year":"2022","unstructured":"Megrian D, Taib N, Jaffe AL, et al. Ancient origin and constrained evolution of the division and cell wall gene cluster in Bacteria. Nat Microbiol. 2022;7(12):2114\u201327.","journal-title":"Nat Microbiol"},{"issue":"3","key":"3581_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008623","volume":"17","author":"AJ Harris","year":"2021","unstructured":"Harris AJ, Goldman AD. The very early evolution of protein translocation across membranes. PLoS Comput Biol. 2021;17(3): e1008623.","journal-title":"PLoS Comput Biol"},{"key":"3581_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan society of clinical oncology clinical practice guidelines for antiemesis. Int J Clin Oncol. 2021;26:1\u201317.","journal-title":"Int J Clin Oncol"},{"key":"3581_CR6","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Rese Commun. 2021;26:100278.","journal-title":"Cancer Treat Rese Commun"},{"key":"3581_CR7","first-page":"102195","volume":"2024","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2023;2024:102195.","journal-title":"ESMO Open"},{"issue":"4","key":"3581_CR8","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, et al. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021;4(4):e215250\u2013e215250.","journal-title":"JAMA Netw Open"},{"issue":"1\u20133","key":"3581_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","volume":"689","author":"M Stathis","year":"2012","unstructured":"Stathis M, Pietra C, Rojas C, et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689(1\u20133):25\u201330.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"3581_CR10","first-page":"13","volume":"24","author":"VA Rhodes","year":"1997","unstructured":"Rhodes VA. Criteria for assessment of nausea, vomiting, and retching. Oncol Nursing Forum. 1997;24(7):13\u20139.","journal-title":"Oncol Nursing Forum"},{"issue":"4","key":"3581_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/03007995.2022.2033011","volume":"38","author":"S Halloush","year":"2022","unstructured":"Halloush S, Alhifany AA, Alkhatib NS, et al. Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2022;38(4):571\u20137.","journal-title":"Curr Med Res Opin"},{"key":"3581_CR12","unstructured":"MASCC\/ESMO, Atiemetic Guidelines, 2013."},{"issue":"9","key":"3581_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1159\/000531318","volume":"101","author":"T Hayashi","year":"2023","unstructured":"Hayashi T, Shimokawa M, Matsuo K, et al. Effectiveness of palonosetron, 1-day dexamethasone, and aprepitant in patients undergoing carboplatin-based chemotherapy. Oncology. 2023;101(9):584\u201390.","journal-title":"Oncology"},{"issue":"3","key":"3581_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00520-015-2905-4","volume":"24","author":"Y Kosaka","year":"2016","unstructured":"Kosaka Y, Tanino H, Sengoku N, et al. Phase II randomized, controlled trial of 1 day versus 3 days of DEX combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer. 2016;24(3):1405\u201311.","journal-title":"Support Care Cancer"},{"issue":"2","key":"3581_CR15","first-page":"84","volume":"8","author":"K Anvari","year":"2015","unstructured":"Anvari K, Seilanian-Toussi M, Hosseinzad-Ashkiki H, et al. A comparison of 5-HT3 receptor antagonist and metoclopramide in the patients receiving chemotherapeutic regimens including CMF, CAF and CHOP. Iran J Cancer Prev. 2015;8(2):84\u20138.","journal-title":"Iran J Cancer Prev"},{"key":"3581_CR16","unstructured":"Miller AG, Balchunis RJ. Phenazine dyes: US5428161. In the 1995-06-27."},{"issue":"7","key":"3581_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J, et al. NCCN guidelines insights: antiemesis, version 2. J Natl Compr Canc Netw. 2017;15(7):883\u201393.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"3581_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jopan.2014.11.013","volume":"30","author":"V Milnes","year":"2015","unstructured":"Milnes V, Gonzalez A, Amos V. Aprepitant: a new modality for the prevention of postoperative nausea and vomiting: an evidence-based review. J Perianesth Nurs. 2015;30(5):406\u201317.","journal-title":"J Perianesth Nurs"},{"issue":"8","key":"3581_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day DEX for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trials. Support Care Cancer. 2011;19(8):1217\u201325.","journal-title":"Support Care Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03581-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:21:54Z","timestamp":1738254114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03581-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03581-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was approved by the Ethics Committee of The 1st Affiliated Hospital of Wenzhou Medical University (ethic code: KY2022-R022) and complied with the guidelines outlined in the declaration of Helsinki. The written consent was received from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors state that there are no financial, personal, or professional Conflict of interest that may hinder this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}